

**Title:** Patients with presumed tuberculosis in sub-Saharan Africa that are not diagnosed with tuberculosis: a systematic review and meta-analysis

Jayasooriya S<sup>1</sup>, Dimambro-Denson F<sup>2</sup>, Beecroft C<sup>3</sup>, J Balen<sup>3</sup>, Awokola B<sup>4</sup>, Mitchell C<sup>1</sup>, Kampmann B<sup>4</sup>, Campbell F<sup>3</sup>, Dodd PJ<sup>3\*</sup>, Mortimer K<sup>5\*</sup>

\* Joint senior authors

<sup>1</sup> Academic Department of Primary Care, The University of Sheffield, UK

<sup>2</sup> The Medical School, The University of Sheffield

<sup>3</sup> School of Health and Related Research, The University of Sheffield

<sup>4</sup> Medical Research Council The Gambia at the London School of Tropical Medicine Hygiene

<sup>5</sup> Liverpool School of Tropical Medicine, University of Liverpool, UK

## **Abstract:**

**Background** Many patients in sub-Saharan Africa whom a diagnosis of tuberculosis is considered are subsequently not diagnosed with tuberculosis. The proportion of patients this represents, and their alternative diagnoses, have not previously been systematically reviewed.

**Methods** We searched four databases from inception to April 27, 2020, without language restrictions (PROSPERO: CRD42018100004). We included all adult pulmonary tuberculosis diagnostic studies from sub-Saharan Africa, excluding case series and inpatient studies. We extracted the proportion of patients with presumed tuberculosis subsequently not diagnosed with tuberculosis and any alternative diagnoses received. We conducted a random-effects meta-analysis to obtain pooled estimates stratified by passive and active case finding.

**Results** Our search identified 1799 studies, of which 18 studies with 14527 participants from 10 African countries were included. The proportion of patients with presumed tuberculosis subsequently not diagnosed with tuberculosis was 48.5% (95% CI 38.4-56.7) in passive and 92.7% (95% CI 83.1-97.0) in active case finding studies. This proportion increased with declining numbers of clinically diagnosed tuberculosis cases. Past history of tuberculosis was documented in only 55% of studies, with just five out of 18 reporting any alternative diagnoses.

**Discussion** Nearly half of all patients with presumed tuberculosis in sub-Saharan Africa do not have a final diagnosis of active tuberculosis. This proportion may be higher when active case finding strategies are used. Little is known about the healthcare needs of these patients. Research is required to better characterise these patient populations and plan health system solutions that meet their needs.

## **Funding**

NIHR, UK MRC

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Introduction:

The differential access to high quality diagnostics experienced in most low- middle-income countries (LMICs) illustrate important and growing global health disparities.<sup>1</sup> Diagnostic tests are often not accessible, affordable or designed for application in LMICs forming a barrier to providing high-quality healthcare. Access to accurate diagnostics for a range of diseases is a cornerstone of high-quality patient care, enabling appropriate timely management, inclusive of transmission control in the case of communicable disease. Pulmonary tuberculosis is a highly prevalent poverty-related communicable disease that lays bare many of the diagnostic challenges faced in LMICs, not least because of non-specific symptoms at presentation.<sup>2</sup>

Patients with presumed tuberculosis are adults or children evaluated for active tuberculosis with suggestive signs and symptoms, such as cough, fever, night sweats, weight loss, haemoptysis and fatigue. While sputum culture remains the bacteriological reference standard for tuberculosis diagnostics, it is a costly, lengthy process and in LMICs is usually only available in central reference laboratories. At local clinics, a reliance on smear microscopy is being replaced by rapid diagnostics such as Xpert MTB/RIF and Xpert MTB/RIF Ultra nucleic acid amplification tests (sensitivity 85%, specificity 98%).<sup>3</sup> Despite these advances, only 57% of global pulmonary tuberculosis cases are bacteriologically confirmed, the rest are clinically diagnosed with negative or no bacteriological testing and notified to the World Health Organisation (WHO) as such. Whereas in high income settings 80% of pulmonary tuberculosis cases are confirmed bacteriologically.<sup>4</sup> The WHO describes the use of both passive and active case finding strategies to detect tuberculosis cases.<sup>2</sup> Passive case finding relies on symptomatic patients seeking medical care by presenting to health services, whereas active case finding involves community-based screening of high risk patients who would not otherwise seek healthcare.

A proportion of patients with presumed tuberculosis are found not to have tuberculosis, following both bacteriological and clinical investigation. This proportion is likely to depend on tuberculosis prevalence, case finding strategies (passive or active) and other context-specific factors such as access to alternative diagnostics. A community study in Malawi demonstrated that only 10-20% of patients presenting to primary care with a persistent cough had tuberculosis.<sup>5</sup> More recent observational data from The Gambia<sup>6</sup> showed that nearly half of all patients with presumed tuberculosis did receive a final diagnosis of tuberculosis. A range of alternative diagnoses - predominantly respiratory - were described, but importantly, non-respiratory diagnoses such as heart failure, malignancy and renal failure were also noted. Furthermore, in 36% of patients not diagnosed with tuberculosis, no alternative diagnosis was made. Minimal health care was afforded to these patients beyond screening for tuberculosis and Human Immunodeficiency Virus (HIV). The burden of ill-health in patients with presumed tuberculosis subsequently found not to have tuberculosis and their on-going engagement with health systems has been largely overlooked. While national guidelines exist for patients that receive a negative sputum smear microscopy result, these focus on further elucidating active tuberculosis cases rather than exploring alternative diagnoses. The rapid rise of non-

communicable disease – including chronic respiratory diseases<sup>1</sup> – in tuberculosis endemic areas, means patients presenting with presumed tuberculosis may increasingly have alternative health issues that require investigation and management, once tuberculosis is ruled out.

Since the Alma Ata declaration, recognising primary healthcare as key to attaining the goal of ‘health for all’, there have been several strategies addressing lung health through service integration and guidance. These include the Practical Approach to Lung Health (PAL) WHO strategy,<sup>7</sup> and The Practical Approach to Care Kit (PACK).<sup>8</sup> The former advocates for the integration of alternative diagnostics for other respiratory conditions within national tuberculosis programmes. The latter focuses on strengthening primary care provision in LMICs. The roll-out of these strategies in sub-Saharan Africa (sSA), where health systems remain fragmented and often dependent on externally funded vertical (communicable) disease control programmes, has been slow. Despite the longstanding existence of PAL, when patients with chronic respiratory symptoms present to health services in sSA, in practice they are faced with limited-service provision that often offers little in the way of alternative diagnostics and follow-on care, aside from an assessment for tuberculosis. While opportunities exist to build and integrate context-specific evidence-based healthcare interventions into tuberculosis services, it is essential to first understand the underlying cause/s of presumptive tuberculosis symptoms when they are not the result of active tuberculosis. The aim of this study was to undertake a systematic review of the evidence describing the number and nature of alternative final diagnoses among patients with presumed tuberculosis in sSA.

## **Methods:**

### **Search strategy and selection criteria**

We performed a systematic review and meta-analysis of the evidence in accordance with PRISMA guidance. PROSPERO registration: CRD42018100004.<sup>9</sup> We searched Ovid Medline, Embase, Cumulative Index of Nursing and Allied Health Literature (CINAHL) and the Cochrane library. The search strategy involved Medical Subject Heading and free text terms relating to the concepts of WHO tuberculosis symptoms (such as “chronic cough”, “fever” and “weight loss”), diagnostics (such as “diagnos\*”, “sensitivity” and “specificity”), tuberculosis and utilised filters for North,<sup>10</sup> East,<sup>11</sup> South,<sup>12</sup> West<sup>13</sup> and Central Africa.<sup>14</sup> The full Medline search strategy is provided in supplementary data and was modified for other databases. Human studies that met the inclusion criteria from inception to April 27, 2020 were included. No language restrictions were applied.

We included all studies (Diagnostic, Cohort and Observational) conducted in sSA enrolling adult ( $\geq 15$  years old) patients with presumed tuberculosis presenting with symptoms (cough  $> 2$  weeks or any one of cough, fever, weight loss, night sweats or haemoptysis). Duplicate articles, research on non-human subjects, in-patient settings, articles reporting exclusively paediatric, extra-pulmonary, pregnant, prison or diabetic populations, and any studies irrelevant to tuberculosis and diagnostics not set in sSA were excluded. Narrative reviews, case reports, case series and studies reporting only smear microscopy diagnostics or screening with chest radiographs as opposed to symptoms were also excluded. This decision was based on recognition of poor access to high-quality radiography equipment and expert interpretation in sSA. Widespread use of low-quality radiography has been a barrier to large-scale programmatic use in tuberculosis programmes throughout sSA.

We screened citations of relevant articles and systematic reviews to identify additional studies. All articles identified by the initial search underwent title and abstract screening. Full-text review of potentially relevant articles was conducted. This was performed by two independent reviewers (SJ, FDD), where a third reviewer (CM) was called upon if a consensus could not be reached. If multiple studies used the same dataset or populations, we included the most comprehensive study with the largest number of participants and excluded the others. Multi-site studies were included where data from sSA sites were individually extractable from the total number of participants.

### **Data analysis:**

Data extraction was performed by two independent reviewers (SJ and FDD) and compared, disagreements were resolved in the first instance by discussion and a third reviewer (CM) called upon if consensus could not be reached. A piloted standardised data extraction form was used to collect information from all eligible studies. All non-English language studies were translated using an online document translator.<sup>15</sup>

For each eligible study we extracted the year of publication, first authors name, mean or median age, proportion of male participants, study country, study setting (general or district hospital, local health centre or community), total number of participants eligible and included, diagnostic test used (culture or GeneXpert), number of patients with and without a diagnosis of tuberculosis disease (Bacteriologically confirmed or clinical) and their HIV rates, where available. Specific details of alternative diagnoses made, and their management were extracted. WHO Global Health Observatory data provided tuberculosis and HIV incidence estimates in-country during the years studies were undertaken and if they spanned more than a year the higher annual value used.

Included studies risk of bias was evaluated using a tool specifically for prevalence studies developed by the Joanna Briggs Institute.<sup>16</sup> Each study was independently assessed according to ten items of methodological quality.

We used WHO case definitions for tuberculosis case reporting. These are bacteriologically confirmed tuberculosis cases and clinically diagnosed tuberculosis cases. All study participants included were tested for tuberculosis therefore clinically diagnosed tuberculosis cases in this review include patients with negative bacteriological results only and not patients that have not undergone testing.

All data analyses were done using R (version 4.0.2) and the metafor package version 2.4-0. We stratified random-effects meta-analyses of the proportion of patients with presumed tuberculosis found not to have tuberculosis by passive or active case finding, and whether cases found passively included clinically diagnosed cases. Meta-regression was used to assess the association between the proportion of patients with presumed tuberculosis subsequently found not to have tuberculosis and the proportion of clinically diagnosed tuberculosis cases, as well as with matched country-year estimates of per capita tuberculosis incidence and HIV prevalence.

## Results:

Our search yielded 1799 articles. 246 duplicate articles were removed (Figure 1). After screening abstracts and titles, we excluded 1204 articles that were not relevant. After screening full texts, we excluded an additional 331 articles that did not meet the eligibility criteria. Therefore, 18 articles with 14527 participants from 10 African countries were included in this systematic review and meta-analysis. Bacteriologically confirmed tuberculosis refers to sputum culture positivity in all but one study<sup>6</sup> that used Xpert MTB/RIF.

No studies were excluded following a risk of bias assessment (Supplementary data). All reporting 70% minimum study population coverage for tuberculosis diagnostic testing. Theron et al. (2011)<sup>17</sup> and Ling et al. (2011)<sup>18</sup> reported consecutive presumptive tuberculosis patient recruitment of 480 over 4yrs and 398 over 5yrs respectively. It was unclear how sampling was performed (breaks during sampling or sampled on certain days) and clinic sizes were not stated that could account for the long study periods with relatively low recruitment numbers.

There were seven studies including (Table 1a)<sup>6,17,19-23</sup> and five studies not including (Table 1b)<sup>18,24-27</sup> clinically diagnosed tuberculosis cases that used passive case finding strategies. Of the five studies (Table 1b) not including clinically diagnosed tuberculosis cases, only Dorman et al. (2018)<sup>25</sup> did not document whether a clinical assessment was performed. Ling et al. (2011),<sup>18</sup> Lawson et al. (2008),<sup>27</sup> Hanrahan et al. (2014)<sup>26</sup> and Cuevas et al. (2011)<sup>24</sup> did perform a clinical assessment but reported no cases of clinically diagnosed tuberculosis. The proportion of patients with presumed tuberculosis subsequently found not to have tuberculosis increased with declining numbers of clinically diagnosed tuberculosis cases ( $P < 0.0001$ ).

There were four active case-finding studies without any clinically diagnosed tuberculosis cases (Table 2). Three studies were conducted in Ethiopia reporting clinical assessments, but no clinically diagnosed tuberculosis cases found.<sup>28-31</sup> No clinical assessments were reported by Sekandi et al. in Uganda.<sup>31</sup>

Figure 2 shows included studies and summary estimates grouped by passive and active case-finding. Passive case finding studies including clinically diagnosed tuberculosis cases (Table 1a) are shown in the top section of Figure 2 with estimates ordered by this proportion. The summary proportion of patients with presumed tuberculosis subsequently found not to have tuberculosis was lower in passive case finding studies that included clinically diagnosed tuberculosis cases (Table 1a) compared to those that did not (Table 1b), 48.5% (CI 38.4-56.7) versus 70.5% (CI 60.9-78.6) (Figure 2). Active case finding studies had higher proportions of patients with presumed tuberculosis subsequently found not to have tuberculosis, 92.7% (CI: 83.1-97.0) (Table 2, Figure 2). Among passive case finding studies, there were no statistically significant associations at the 0.05 level between country-year estimates of tuberculosis incidence or HIV prevalence. Heterogeneity was high ( $I^2 > 95\%$  in all cases).

A further two articles included patients with presumed tuberculosis that were already smear negative on microscopy (Table 3). Affolabi et al. (2011)<sup>32</sup> did not include and Huerga et al. (2012)<sup>33</sup> included clinically diagnosed tuberculosis cases, with 89% and 61% of patients with presumed tuberculosis subsequently found not to have tuberculosis respectively.

Only five studies reported diagnoses other than active tuberculosis (Table 4).<sup>6,20,21,26,33</sup> Two described non-tuberculous mycobacteria and one *Pneumocystis jirovecii* pneumonia as the only alternative diagnoses.<sup>20,26,33</sup> Jayasooriya et al. (2019)<sup>6</sup> and Munyati et al. (2005)<sup>21</sup> described a range of diagnoses which were predominantly respiratory, but importantly non-respiratory diagnoses such as heart failure, malignancy and renal failure were noted. Neither study performed spirometry. Four out of the five studies reported management of patients with presumed tuberculosis subsequently found not to have tuberculosis, two stating as clinically indicated. Notably, Affolabi et al. (2011)<sup>32</sup> and Huerga et al. (2012)<sup>33</sup> reported giving empirical antibiotics to all patients subsequently found not to have active tuberculosis amounting to mass administration of antibiotics to 207 and 380 patients respectively. Only 10/18 (55%) studies recorded historical tuberculosis episodes, and none recorded the number of times individuals had undergone previous tuberculosis testing.

## Discussion:

Our findings demonstrate that almost half of patients with presumed tuberculosis in sSA were not given a final diagnosis of active tuberculosis. While this proportion varied according to study it was not predicted by country incidence of tuberculosis or HIV. Only five of the identified studies attempted to characterise patients with presumed tuberculosis who were subsequently found not to have tuberculosis seeking alternative diagnoses.<sup>6,20,21,26,33</sup> Of these, only two reported a breadth of alternative diagnoses.<sup>6,21</sup> In both these cases, clinical judgement was used to decide on investigations performed, rather than a standardised approach, and in no instances was spirometry conducted.<sup>6,21</sup> Despite this cardiac pathology was described in both studies, consistent with a retrospective review of radiological findings in a Kenyan cohort identifying a wide variety of abnormalities unrelated to active tuberculosis.<sup>34</sup>

The proportion of patients with presumed tuberculosis subsequently found not to have tuberculosis was inversely associated with the number of clinically diagnosed tuberculosis cases. While this could imply overdiagnosis of active tuberculosis, through reliance on clinical judgement, it is important to note that LMICs have high rates of active tuberculosis.<sup>4</sup> The lack of access to high quality health systems and diagnostics in sSA means there is likely to be a high burden of unrecognised diseases of all causes and unmet clinical need in the general population.<sup>35</sup> Therefore, patients with presumed tuberculosis – symptomatic by definition – risk having the true causes of their symptoms neglected if they are not due to active tuberculosis.<sup>6,21</sup> An approach used in two included studies was mass administration of empirical antibiotics to several hundreds of patients with presumed tuberculosis subsequently not diagnosed with tuberculosis. With increasing antimicrobial resistance recognised as one of the biggest public health challenges of our time, nuanced strategies to mitigate against administering unnecessary antibiotics are vital. The implications for missing active tuberculosis are clear, yet those of incorrectly labelling people as having active tuberculosis, and/or missing other health conditions also need to be taken into consideration. Furthermore, how this relates to paediatric tuberculosis, where a high proportion of empirical tuberculosis treatment occurs, is unknown.

The few included studies that used active case finding strategies showed much higher proportions of patients with presumed tuberculosis subsequently found not to have tuberculosis than those that used passive case finding. This can in part be explained by active case finding studies reporting only bacteriologically confirmed tuberculosis cases. A WHO-commissioned systematic review reported general population community-based active case finding studies set in sSA<sup>36</sup> detected bacteriologically (often smear) confirmed tuberculosis alone, and none reported clinically diagnosed tuberculosis cases. When comparing active with passive case finding studies that also reported only bacteriologically confirmed tuberculosis cases, the former still had a higher proportion of patients with presumed tuberculosis subsequently found not to have tuberculosis. These findings imply that active case finding strategies encounter more community members with unidentified health issues that have non-specific symptoms similar to those of active tuberculosis.



Systematic active screening of high-risk groups is a central component of the WHO End Tuberculosis Strategy and the aforementioned systematic review suggests that community-based active case-finding might be effective at detecting active tuberculosis early.<sup>36</sup> However, the emphasis on active case-finding strategies in sSA should take into consideration patients with presumed tuberculosis subsequently found not to have tuberculosis. Improving the ability of local health systems to respond proactively to these patients, alongside clinically diagnosed tuberculosis cases is imperative.

Just over half of included studies captured prior histories of tuberculosis and none indicated how many times (if at all) patients had been previously tested for tuberculosis. Considering the former is important for assessing the risk of active tuberculosis in patients with presumed tuberculosis, recording this in future research is essential, as interpretation is limited by the incompleteness of these data. The impact of tuberculosis across the life course, evidenced by increased all-cause mortality post infection<sup>37</sup> and post-tuberculosis lung disease,<sup>38</sup> in addition to implications for future test result interpretation, specifically Xpert MTB/RIF and Xpert MTB/RIF Ultra, also necessitate this. Moreover, patients with presumed tuberculosis subsequently found not to have tuberculosis will include some of the estimated 155 million patients globally alive today post tuberculosis<sup>39</sup> and provide an opportunity to identify them allowing for provision of on-going care.

This work raises ethical issues around the inclusion of patients, not only those presumed to have tuberculosis, in research studies conducted in settings where limited primary care is available. This is especially true in view of rising chronic respiratory diseases, a major group of non-communicable diseases causing an estimated 3.9 million deaths in 2017<sup>40</sup> and a disproportionately high burden in LMICs.<sup>1</sup> It is critical that the duty of care afforded as a minimum to symptomatic unwell patients screening out of studies in such settings should be taken into consideration during research planning, offering for example in this case, enhanced standards of care and follow-up for patients subsequently found not to have tuberculosis. This will require improved collaboration between researchers and health system actors as well as greater consideration of the study participant's health needs.

There are limitations to our review. We found only two studies with stated objectives to describe patients with presumed tuberculosis subsequently found not to have tuberculosis. Most studies were designed to capture patients with active tuberculosis and therefore understandably data on those not included as final study participants was not always comprehensive. In particular we highlight that where data was not recorded, it does not always equate to not being performed. However, this absence of data further supports our conclusion that there is a critical lack of reported data on patients with presumed tuberculosis subsequently found not to have tuberculosis.

This systematic review of the literature highlights that at least half of all patients with presumed tuberculosis attending services in sSA are not given a diagnosis of

active tuberculosis; many not receiving any alternative diagnoses. In sSA 1.4million tuberculosis cases were notified in 2019, our data suggests this figure represents only half of all symptomatic patients presenting with presumptive tuberculosis. Therefore, a further 1.4million may have accessed health systems but not received appropriate care. It is critical we address this by characterising the clinical needs among these hitherto neglected patients, in order to plan appropriate health system solutions. Future studies should explore patient experiences to better understand how these influence subsequent care seeking behaviours and health system engagement. Generating such data would help facilitate integration of services for non-communicable chronic respiratory diseases with tuberculosis programmes.

## **Contributors**

SJ formulated the research questions with input from BK and KM

SJ, CB formulated the search strategy

SJ, FDD screened articles and data extracted with input from FC.

PJD synthesised data with input from SJ

All authors (SJ, FDD, CB, JB, BA, CM, BK, FC, PJD & KM) contributed to data interpretation and drafting the manuscript.

## **Declaration of interests**

I/We declare no competing interests.

## **Acknowledgements**

We thank the NIHR Global Health Research Unit on Lung Health and tuberculosis in Africa at LSTM - "IMPALA" for helping to make this work possible. In relation to IMPALA (grant number 16/136/35) specifically: This research was funded by the National Institute for Health Research (NIHR) (IMPALA, grant reference 16/136/35) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care.

PJD was supported by a fellowship from the UK Medical Research Council (MR/P022081/1); this UK funded award is part of the EDCTP2 programme supported by the European Union.

SJ was supported by an NIHR Clinical Lectureship Award.

## References

1. Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. *Lancet* 2021;397:928-40.
2. Systematic Screening for Active Tuberculosis: Principles and Recommendations. Geneva 2013.
3. Horne DJ, Kohli M, Zifodya JS, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst Rev* 2019;6:CD009593.
4. WHO. Global Tuberculosis Report: executive summary 2020.
5. Banda HT, Thomson R, Mortimer K, et al. Community prevalence of chronic respiratory symptoms in rural Malawi: Implications for policy. *PloS one* 2017;12:e0188437.
6. Jayasooriya S, Jobe A, Badjie S, et al. The burden of non-TB lung disease presenting to TB clinics in The Gambia: preliminary data in the Xpert((R)) MTB/Rif era. *Public health action* 2019;9:166-8.
7. Banda H, Robinson R, Thomson R, Squire SB, Mortimer K. The 'Practical Approach to Lung Health' in sub-Saharan Africa: a systematic review. *Int J Tuberc Lung Dis* 2016;20:552-9.
8. Cornick R, Picken S, Watrus C, et al. The Practical Approach to Care Kit (PACK) guide: developing a clinical decision support tool to simplify, standardise and strengthen primary healthcare delivery. *BMJ Glob Health* 2018;3:e000962.
9. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
10. Campbell S. A Filter to Retrieve Studies Related to Northern Africa from the OVID Medline Database. Edmonton, AB: University of Alberta, 2017.
11. Campbell S. A Filter to Retrieve Studies Related to Eastern Africa from the OVID Medline Database. Edmonton, AB: University of Alberta, 2018.
12. Campbell S. A Filter to Retrieve Studies Related to Southern Africa from the OVID medline Database. Edmonton, AB: University of Alberta, 2017. .
13. Campbell S. A Filter to Retrieve Studies Related to Western Africa from the OVID MEDLINE Database. Edmonton, AB: University of Alberta, 2017. .
14. Campbell S. A Filter to Retrieve Studies Related to Middle Africa from the OVID Medline Database. Edmonton, AB: University of Alberta, 2017.
15. <https://www.onlinedoctranslator.com/en/>.
16. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid Based Healthc* 2015;13:147-53.
17. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. *Am J Respir Crit Care Med* 2011;184:132-40.
18. Ling DI, Pai M, Davids V, et al. Are interferon-gamma release assays useful for diagnosing active tuberculosis in a high-burden setting? *Eur Respir J* 2011;38:649-56.
19. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of

- tuberculosis and multidrug resistance: a multicentre implementation study. *Lancet* 2011;377:1495-505.
20. Bruchfeld J, Aderaye G, Palme IB, et al. Evaluation of outpatients with suspected pulmonary tuberculosis in a high HIV prevalence setting in Ethiopia: clinical, diagnostic and epidemiological characteristics. *Scand J Infect Dis* 2002;34:331-7.
  21. Munyati SS, Dhoba T, Makanza ED, et al. Chronic cough in primary health care attendees, Harare, Zimbabwe: diagnosis and impact of HIV infection. *Clin Infect Dis* 2005;40:1818-27.
  22. Nliwasa M, MacPherson P, Chisala P, et al. The Sensitivity and Specificity of Loop-Mediated Isothermal Amplification (LAMP) Assay for Tuberculosis Diagnosis in Adults with Chronic Cough in Malawi. *PloS one* 2016;11:e0155101.
  23. Reither K, Saathoff E, Jung J, et al. Evaluation of Diagnos TB AG, a flow-through immunoassay for rapid detection of pulmonary tuberculosis. *Int J Tuberc Lung Dis* 2010;14:238-40.
  24. Cuevas LE, Yassin MA, Al-Sonboli N, et al. A multi-country non-inferiority cluster randomized trial of frontloaded smear microscopy for the diagnosis of pulmonary tuberculosis. *PLoS Med* 2011;8:e1000443.
  25. Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. *Lancet Infect Dis* 2018;18:76-84.
  26. Hanrahan CF, Theron G, Bassett J, et al. Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. *Am J Respir Crit Care Med* 2014;189:1426-34.
  27. Lawson L, Yassin MA, Thacher TD, et al. Clinical presentation of adults with pulmonary tuberculosis with and without HIV infection in Nigeria. *Scand J Infect Dis* 2008;40:30-5.
  28. Deribew A, Abebe G, Apers L, et al. Prevalence of pulmonary TB and spoligotype pattern of Mycobacterium tuberculosis among TB suspects in a rural community in Southwest Ethiopia. *BMC Infect Dis* 2012;12:54.
  29. Hamusse S, Demissie M, Teshome D, Hassen MS, Lindtjorn B. Prevalence and Incidence of Smear-Positive Pulmonary Tuberculosis in the Hetosa District of Arsi Zone, Oromia Regional State of Central Ethiopia. *BMC Infect Dis* 2017;17:214.
  30. Merid Y, Mulate YW, Hailu M, et al. Population-based screening for pulmonary tuberculosis utilizing community health workers in Ethiopia. *Int J Infect Dis* 2019;89:122-7.
  31. Sekandi JN, List J, Luzze H, et al. Yield of undetected tuberculosis and human immunodeficiency virus coinfection from active case finding in urban Uganda. *Int J Tuberc Lung Dis* 2014;18:13-9.
  32. Affolabi D, Akpona R, Odoun M, et al. Smear-negative, culture-positive pulmonary tuberculosis among patients with chronic cough in Cotonou, Benin. *Int J Tuberc Lung Dis* 2011;15:67-70.
  33. Huerga H, Varaine F, Okwaro E, et al. Performance of the 2007 WHO algorithm to diagnose smear-negative pulmonary tuberculosis in a HIV prevalent setting. *PloS one* 2012;7:e51336.
  34. Mungai BN, Joeke E, Masini E, et al. 'If not TB, what could it be?' Chest X-ray findings from the 2016 Kenya Tuberculosis Prevalence Survey. *Thorax* 2021.

35. Kruk ME, Gage AD, Arsenault C, et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. *Lancet Glob Health* 2018;6:e1196-e252.
36. Burke RM, Nliwasa M, Feasey HRA, et al. Community-based active case-finding interventions for tuberculosis: a systematic review. *Lancet Public Health* 2021.
37. Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. *Lancet Infect Dis* 2019;19:1129-37.
38. Meghji J, Lesosky M, Joekes E, et al. Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study. *Thorax* 2020;75:269-78.
39. Dodd PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, Seddon JA. Quantifying the global number of tuberculosis survivors: a modelling study. *Lancet Infect Dis* 2021.
40. Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1736-88.





Figure 1: Study Selection



**Figure 2: Random-effects meta-analyses of the proportion of patients with presumptive tuberculosis not diagnosed as tuberculosis.** Studies are stratified by passive or active case finding. Passive case finding studies including clinically diagnosed tuberculosis are shown with estimates ordered by this proportion.



	Study Title	Study Type	Country	Age (median , IQR)	Male (%)	Setting	Presumptive TB (included/ eligible)	Diagnosed with Tuberculosis				Not Tuberculosis	
								Laboratory (bacteriological)	Clinical	Total	HIV	Total	HIV
Boehme et al. (2011) <sup>19</sup>	Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study	Cross-sectional Study	South Africa	36, 29-46	51	Health Centre	1968/1968	473	824	1297	NR	671	NR
			Uganda	32 26-38	54	General Hospital	307/307	146	17	163	NR	144	NR
Bruchfeld et al. (2002) <sup>20</sup>	Evaluation of outpatients with suspected pulmonary tuberculosis in a high HIV prevalence setting in Ethiopia: Clinical, Diagnostic and epidemiological characteristics	Cross-sectional study	Ethiopia	33 <sup>‡</sup>	56.3 <sup>‡</sup>	General Hospital	493/509	168	113	281	148	212	73
Jayasooriya et al. (2019) <sup>6</sup>	The burden of non-TB lung disease presenting to TB clinics in the Gambia: Preliminary data in the Xpert MTB/rif era	Cross-sectional Study	The Gambia	40 <sup>‡</sup> 28-47	50 <sup>‡</sup>	Research Clinic	233/239	114	17	131	17	102	12

Munyati et al. (2005) <sup>21</sup>	Chronic cough in primary health care attendees, Hasrare, Zimbabwe: diagnosis and impact of HIV infection	Cross-sectional Study	Zimbabwe	33	48	Health Centre	544/550	184	50	234	207	310	247
Nliwasa et al. (2016) <sup>22</sup>	The Sensitivity and Specificity of Loop-Mediated Isothermal Amplification (LAMP) Assay for Tuberculosis Diagnosis in Adults with Chronic Cough in Malawi	Cross-sectional Study	Malawi	32 25-41	48	Health Centre	233/273	53	3	56	24	177	97
Reither et al. (2010) <sup>23</sup>	Evaluation of diagnosis TB AG, a flow-through immunoassay for rapid detection of pulmonary tuberculosis	Cross-sectional Study	Tanzania	36	47.4	Research Clinic	171/202	45	33	78	51	93	50
Theron et al. (2011) <sup>17</sup>	Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high prevalence setting	Cross-sectional Study	South Africa	36 18-83 <sup>†</sup>	68	Health Centre	480/496	141	182	323	46	157	84

\* Age, mean (+/- SD), <sup>†</sup>(range) <sup>‡</sup> Not TB patients, <sup>§</sup>Not all tested, denominator, NR not recorded, HIV Human Immunodeficiency Virus

Table 1a. Tuberculosis studies meeting inclusion criteria using passive case finding including clinically diagnosed tuberculosis cases

	Study Title	Study Type	Country	Age (median , IQR)	Male (%)	Setting	Presumptive TB (included/ eligible)	Diagnosed with Tuberculosis				Not Tuberculosis	
								Laboratory (bacteriological)	Clinical	Total	HIV	Total	HIV
Cuevas et al. (2011) <sup>24</sup>	A multi-country non-inferiority cluster randomized trials of frontloaded smear microscopy for the diagnosis of pulmonary tuberculosis	Cluster Randomised Trial	Ethiopia	33.7* (+/-14.1)	52.8	Health Centre	1770/1909	586	0	586	0	1184	NR
			Nigeria	34.4* (+/-10.7)	51.9	Health Centre	1196/1238	233	0	233	0	963	NR
Dorman et al. (2018) <sup>25</sup>	Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study	Cross-sectional Study	South Africa (Cape Town)	41, 34-49	41	District Hospital	150/152	27	NR	27	NR	125	NR
			South Africa (Johannesburg)	34, 30-43	63	District Hospital	234/234	74	NR	74	NR	160	NR
			Kenya	33, 26-44	51	District Hospital	135/135	28	NR	28	NR	107	NR
			Uganda	30, 26-39	64	District Hospital	181/181	67	NR	67	NR	114	NR
Hanrahan et al. (2014) <sup>26</sup>	Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression	Cross-sectional Study	South Africa	37, 29-46	38	Health Centre	2091/2406	406	0	406	NR	1685	NR
Lawson et al. (2008) <sup>27</sup>	Clinical presentation of adults with pulmonary tuberculosis with and	Cross-sectional Study	Nigeria	33* (+/-10)	61	District Hospital	1186/1321	731	0	731	329 <sup>s</sup> /625	455	217 <sup>s</sup> /377

	without HIV infection in Nigeria												
Ling et al (2011) <sup>18</sup>	Are interferon-gamma release assays useful for diagnosing active tuberculosis in a high-burden setting?	Cross-sectional Study	South Africa	40* (+/-12)	66	Health Centre	395/500	138	0	138	43	257	65

\* Age, mean (+/- SD), †(range) ‡ Not TB patients, §Not all tested, denominator, NR not recorded, HIV Human Immunodeficiency Virus

Table 1b. Tuberculosis studies meeting inclusion criteria using passive case finding not including clinically diagnosed tuberculosis cases

	Study Title	Study Type	Country	Age (median , IQR)	Male (%)	Setting	Presumptive TB (included/ eligible)	Diagnosed with Tuberculosis				Not Tuberculosis	
								Laboratory (bacteriological)	Clinical	Total	HIV	Total	HIV
Deribew et al. (2012) <sup>28</sup>	Prevalence of pulmonary TB and spoligotype pattern of <i>Mycobacterium tuberculosis</i> among TB suspects in a rural community in Southwest Ethiopia	Cross-sectional Study	Ethiopia	41* (+/-16.2)	39.3	Community	428/482	17	0	17	NR	411	NR
Hamusse et al. (2017) <sup>29</sup>	Prevalence and Incidence of Smear-Positive Pulmonary Tuberculosis in the Hetosa District of Arsi Zone, Oromia Regional State of Central Ethiopia	Cross-sectional Study	Ethiopia	33.3* <sup>†</sup> (+/-16)	51 <sup>†</sup>	Community	1041/1041	43	0	43	0	998	NR
Merid et al. (2019) <sup>30</sup>	Population-based screening of pulmonary tuberculosis utilizing community health workers in Ethiopia	Cross-sectional Study	Ethiopia	36 29-48	35	Health Centre	544/544	34	0	34	0/31 <sup>†</sup>	510	NR
Sekandi et al. (2014) <sup>31</sup>	Yield of undetected tuberculosis and human immunodeficiency virus co-infection from active case finding in urban Uganda	Cross-sectional Study	Uganda	24 20-30	37.2	Community	160/199	39	NR	39	13	121	32

\*Age, mean (+/- SD), <sup>†</sup> Age and Male (%) of community screened, NR not reported, HIV Human Immunodeficiency Virus

Table 2. Tuberculosis studies meeting inclusion criteria using active finding not including clinically diagnosed tuberculosis cases

	Study Title	Study Type	Country	Age (median , IQR)	Male (%)	Setting	Presumptive TB (included/ eligible)	Diagnosed with Tuberculosis				Not Tuberculosis	
								Laboratory (bacteriological)	Clinical	Total	HIV	Total	HIV
Affolabi et al. (2011) <sup>32</sup>	Smear-negative, culture-positive pulmonary tuberculosis among patients with chronic cough in Cotonou, Benin	Cross-sectional Study	Benin	NR	NR	General Hospital	207/251	22	0	22	10	185	81
Huerga et al. (2012) <sup>33</sup>	Performance of the 2007 WHO Alorithm to Diagnose Smear-Negative Pulmonary Tuberculosis in a HIV Prevalent Setting	Cross-sectional Study	Kenya	34 (26-48)	37.1	District Hospital	380/380	61	89	150		230	

\*Age, mean (+/- SD), † Age and Male (%) of community screened, NR not reported, HIV Human Immunodeficiency Virus

Table 3. Tuberculosis studies of smear negative participants meeting inclusion criteria

	Country	Diagnoses	Management	Past history of Tuberculosis	Previous Tuberculosis Testing	WHO estimated incidence (year of study)	
						Tuberculosis (per 100 000)	HIV (per 1000)
Affolabi et al. (2011) <sup>32</sup>	Benin	NR	15days Erythromycin	NR	NR	71	0.69
Boehme et al. (2011) <sup>19</sup>	South Africa	NR	NR	NR	NR	1260	10.29
	Uganda	NR	NR	NR	NR	213	3.55
Bruchfeld et al. (2002) <sup>20</sup>	Ethiopia	8 Pneumocystis pneumonia	NR	66*	NR	NR	1.79
Cuevas et al. (2011) <sup>24</sup>	Ethiopia	NR	NR	NR	NR	296	0.44
	Nigeria	NR	NR	NR	NR	219	0.79
Deribew et al. (2012) <sup>28</sup>	Ethiopia	NR	NR	NR	NR	282	0.41
Dorman et al. (2018) <sup>25</sup>	South Africa (Cape Town)	NR	NR	59	NR	805	5.45
	South Africa (Johanesburg)	NR	NR	55	NR	805	5.45
	Kenya	NR	NR	20	NR	348	1.17
	Uganda	NR	NR	15	NR	201	1.89
Hamusse et al. (2017) <sup>29</sup>	Ethiopia	NR	NR	NR	NR	224	0.25
Hanrahan et al. (2014) <sup>26</sup>	South Africa	9 Non-tuberculous mycobacteria	NR	NR	NR	1200	8.67
Huerga et al (2012) <sup>33</sup>	Kenya	11 Non-tuberculous mycobacteria	5 days Amoxicillin	92	NR	566	2.22
Jayasooriya et al. (2019) <sup>6</sup>	The Gambia	2 Malignancy: 2 Lung 1 Haematological	Clinically indicated	16*	NR	162	1.07
		32 other respiratory tract infections					
		8 Pneumonia					
		4 Asthma					
		2 Pleural effusions					

		1 Lung abscess					
		10 Heart failure					
		2 Structural heart disease					
		1 Ischaemic heart disease					
		2 Chronic renal failure					
		43 Unknown					
Lawson et al. (2008) <sup>27</sup>	Nigeria	NR	NR	NR	NR	219	0.91
Ling et al (2011) <sup>18</sup>	South Africa	NR	NR	NR	NR	1200	8.67
Merid et al. (2019) <sup>30</sup>	Ethiopia	NR	NR	151*	NR	177	0.2
Munyati et al. (2005) <sup>†21</sup>	Zimbabwe	178 Other respiratory tract infections	Clinically indicated	97	NR	607	8.67
		87 bacterial Pneumonia					
		34 Fibrotic lung disease: 28 Post-tuberculous disease 2 Idiopathic diffuse fibrosis					
		26 Asthma					
		8 Pneumocystis pneumonia					
		5 Cryptococcosis					
		15 Heart failure					
		5 Malignancy: 3 Kaposi Sarcoma 1 primary bronchus 1 metastatic breast					
		16 unknown					
Nliwasa et al. (2016) <sup>22</sup>	Malawi	NR	NR	NR	NR	261	3.2
Reither et al (2010) <sup>23</sup>	Tanzania	NR	NR	NR	NR	492	2.75
Sekandi et al. (2014) <sup>31</sup>	Uganda	NR	NR	NR	NR	217	3.7
Theron et al. (2011) <sup>17</sup>	South Africa	NR	NR	158	NR	1270	11.82

\* Past history of Tuberculosis in participants without Tuberculosis, † Participants diagnosed with multiple conditions, NR not reported

Table 4. Tuberculosis studies handling and reporting of patients with presumed tuberculosis found not to have tuberculosis